Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CBP-201 for moderate-to-severe atopic dermatitis in China has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CBP-201

Snippet

Sponsor: Connect Biopharm LLC | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-05-01